You are currently on the new version of our website. Access the old version .
NutrientsNutrients
  • Article
  • Open Access

14 February 2018

Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims on Foods Related to Vision Proposed Under Regulation (EC) 1924/2006

,
,
,
,
,
,
,
,
and
1
The Laboratory of Phytochemicals in Physiology, Department of Food and Drug, University of Parma, 43125 Parma, Italy
2
Department of Medicine and Surgery, Clinical Psychology Unit, University of Parma, 43125 Parma, Italy
3
Clinical Epidemiology Unit, Liver Research Center, Basovizza, 34149 Trieste, Italy
4
Department of Medicine and Surgery, Division of Endocrinology, University of Parma, 43125 Parma, Italy
This article belongs to the Special Issue Nutrition and the Function of the Central Nervous System

Abstract

Adequate visual function has a strong impact on the quality of life of people. Several foods and food components have been hypothesized to play a role in the maintenance of normal visual function and in the prevention of eye diseases. Some of these foods/food components have been the object of a request of authorization for use of health claims under Articles 13(5) or 14 of the Regulation (EC) 1924/2006. Most of these requests have received a negative opinion from the European Food Safety Authority (EFSA) due to the choice of inappropriate outcome variables (OVs) and/or methods of measurement (MMs) applied in the studies used to substantiate the claims. This manuscript refers to the collection, collation and critical analysis of OVs and MMs related to vision. Guidance document and requests for authorization of health claims were used to collect OVs and MMs related to vision. A literature review was performed to critically analyse OVs and MMs, with the aim of defining their appropriateness in the context of a specific claimed effect related to vision. The results highlight the importance of adequate choices of OVs and MMs for an effective substantiation of claims related to visual function.

1. Introduction

Proper vision development and setup are features with strong impacts on practically all aspects of an individual’s life. Blindness and low vision, are recognized as important causes of impairment in high income countries [1]. A recent review has shown that, in high income countries, as well as in in Eastern and Central Europe, blindness and mild and severe vision impairment (MSVI) decreased from 1990 to 2010 from 0.2 to 0.1% (3.314 million to 2.736 million people) and from 1.6 to 1.0% (25.362 million to 22.176 million), respectively [2]. However, MSVI can still lead to dramatic consequences, particularly for younger people. Vision loss, is linked to (i) depression in people more than 20 years old; (ii) a substantial economic burden, particularly for the those who are less than 40 years old [3,4] and (iii) to a dramatic change in the way people perceive their own ability to function independently, hence, in their quality of life [5].
Uncorrected refractive error, followed by cataracts, macular degeneration, glaucoma and diabetic retinopathy, are the most common causes of MSVI. Beyond diabetes, which is one of the biggest nutritional contributors to complete vision loss, a wide range of ocular defects have their origin either in nutritional deficiencies or excess. These conditions have been shown to respond favourably to nutritional components [6].
In this scenario, some food components have been the object of applications for authorization of health claims relevant to Regulation (EC) 1924/2006. Most of these applications have received a negative opinion from the European Food Safety Authority (EFSA), for several reasons that fall into one of these three categories: (i) insufficient characterization of the food/food component; (ii) choice of an inappropriate claimed effect and (iii) insufficient substantiation of the claim, including inadequate sample size or statistical analysis, or choice of inappropriate outcome variables (OVs) and/or methods of measurement (MMs). Based on this consideration, a project has been developed to collect, collate and critically analyse OVs and MMs that have been proposed for the substantiation of health claims, with the aim of improving the quality of applications submitted by applicants to EFSA. Previous papers related to different areas of interest have been already published [7,8,9,10,11]. This manuscript refers to the collection, collation and critical analysis of OVs and MMs related to vision.

2. Materials and Methods: Search Strategy

Guidance document (EFSA 2012), requests for authorization of health claims under Articles 13.5 and 14 of Regulation 1924/2006 related to visual function and comments received during public consultations were screened to collect OVs and MMs. As already described [7], OVs and related MMs were considered only if the food/food constituent(s) were sufficiently characterized and if the claimed effect was considered to be well defined and beneficial. Following this decision tree, one claimed effect with six OVs was evaluated under Article 13.5, whereas two claimed effects with a total of five OVs referred to children development were selected under Article 14.
For the collation, a specific syntax with appropriate keywords was used to create a database of references on PubMed for each OV. These databases were used to critically analyse OVs and MMs which were ranked as: (i) appropriate; (ii) appropriate only in combination with other OVs or MMs; (iii) not appropriate per se; (iv) not appropriate in relation to the specific claimed effect proposed by the applicant(s); (v) useful as supportive evidence for the substantiation of the claimed effect.
Regarding the MMs, all the methods proposed for each OV in the scientific opinion and/or in the guidance document were included in the evaluation, unless the related OV was considered to be inappropriate per se, or for the specific claimed effect. If no methods were proposed or all the proposed methods were considered inappropriate, the best or the most widely used methods were added.

4. Conclusions

Insufficient scientific substantiation of a health claim is one of the most common reasons for a negative response to applications for authorization of a health claim.
This work critically analyses all the OVs and MMs that have been proposed so far in the context of maintenance of vision relevant to Regulation (EC) 1924/2006, as summarized in Table 2. However, independently from the critical analysis of each OV and MM, the use of a battery of OVs (for instance visual acuity and contrast sensitivity) is always preferable, to obtain clearer and more exhaustive evidence on the effect of a food/food component on visual function.
Table 2. Summary of the main findings of the study. Legend: A: appropriate itself; S: only supportive; N: not appropriate for that claimed effect; /: not evaluated (because the outcome variable is not appropriate per se).
The information provided by this work could be used by stakeholders during the design of randomized controlled trials aimed to substantiate health claims related to vision. Moreover, EFSA could use the information to update the related guidance on the scientific requirements for health claims.
However, it is worth repeating that randomized controlled trials should take into account many parameters other than appropriate OVs and related MMs, including an adequate sample size, a proper study design and an adequate statistical analysis.

Acknowledgments

This project has received financial support from the European Food Safety Authority (EFSA), Grant GP/EFSA/NUTRI/2014/01. The present article, however, is under the sole responsibility of the authors. The positions and opinions presented in this article are those of the authors alone and do not necessarily represent the views/any official position or scientific works of EFSA. To find out more about EFSA guidance documents and other scientific outputs of EFSA, please consult its website at: http://www.efsa.europa.eu.

Author Contributions

D.M. was the project developer and wrote the manuscript together with A.I., C.C., D.A. and B.B.; G.B. generated the literature databases and helped with the evaluation of the appropriateness and the validity of the statistics found in the literature studies taken into account; I.Z., M.Ve., D.G., P.M., M.Vi., A.D.C., R.C.B., G.P. and C.P. were experts members of the project team, helped secure the funding and critically read and revised the manuscript; C.P. was the Group Leader for the part of the project related to Neurological and Psychological functions; D.D.R. was the Principal Investigator of the entire project, critically revised the manuscript and had primary responsibility for final content.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Congdon, N.; O’Colmain, B.; Klaver, C.C.W.; Klein, R.; Munoz, B.; Friedman, D.S.; Kempen, J.; Taylor, H.R.; Mitchell, P.; Hyman, L.; et al. Causes and prevalence of visual impairment among adults in the united states. Arch. Ophthalmol. 2004, 122, 477–485. [Google Scholar] [PubMed]
  2. Bourne, R.R.A.; Jonas, J.B.; Flaxman, S.R.; Keeffe, J.; Leasher, J.; Naidoo, K.; Parodi, M.B.; Pesudovs, K.; Price, H.; White, R.A.; et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. Br. J. Ophthalmol. 2014, 98, 629–638. [Google Scholar] [CrossRef] [PubMed]
  3. Wittenborn, J.S.; Zhang, X.Z.; Feagan, C.W.; Crouse, W.L.; Shrestha, S.; Kemper, A.R.; Hoerger, T.J.; Saaddine, J.B.; Study, V.C.-E. The economic burden of vision loss and eye disorders among the United States population younger than 40 years. Ophthalmology 2013, 120, 1728–1735. [Google Scholar] [CrossRef] [PubMed]
  4. Zhang, X.Z.; Bullard, K.M.; Cotch, M.F.; Wilson, M.R.; Rovner, B.W.; McGwin, G.; Owsley, C.; Barker, L.; Crews, J.E.; Saaddine, J.B. Association between depression and functional vision loss in persons 20 years of age or older in the United States, NHANES 2005–2008. JAMA Ophthalmol. 2013, 131, 573–581. [Google Scholar] [CrossRef] [PubMed]
  5. Trento, M.; Passera, P.; Trevisan, M.; Schellino, F.; Sitia, E.; Albani, S.; Montanaro, M.; Bandello, F.; Scoccianti, L.; Charrier, L.; et al. Quality of life, impaired vision and social role in people with diabetes: A multicenter observational study. Acta Diabetol. 2013, 50, 873–877. [Google Scholar] [CrossRef] [PubMed]
  6. Preedy, V. Handbook of Nutrition, Diet and the Eye; Academic Press: Waltham, MA, USA, 2014. [Google Scholar]
  7. Martini, D.; Rossi, S.; Biasini, B.; Zavaroni, I.; Bedogni, G.; Musci, M.; Pruneti, C.; Passeri, G.; Ventura, M.; Di Nuzzo, S.; et al. Claimed effects, outcome variables and methods of measurement for health claims proposed under European community regulation 1924/2006 in the framework of protection against oxidative damage and cardiovascular health. Nutr. Metab. Cardiovasc. Dis. 2017, 27, 473–503. [Google Scholar] [CrossRef] [PubMed]
  8. Martini, D.; Angelino, D.; Cortelazzi, C.; Zavaroni, I.; Bedogni, G.; Musci, M.; Pruneti, C.; Passeri, G.; Ventura, M.; Galli, D.; et al. Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of maintenance of skin function. Nutrients 2018, 10, 7. [Google Scholar] [CrossRef] [PubMed]
  9. Martini, D.; Biasini, B.; Rossi, S.; Zavaroni, I.; Bedogni, G.; Musci, M.; Pruneti, C.; Passeri, G.; Ventura, M.; Galli, D.; et al. Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under European Community Regulation 1924/2006 in the area of appetite ratings and weight management. Int. J. Food Sci. Nutr. 2017, 28, 1–21. [Google Scholar] [CrossRef] [PubMed]
  10. Martini, D.; Guareschi, C.; Biasini, B.; Bedogni, G.; Galli, C.; Angelino, D.; Marchi, L.; Zavaroni, I.; Pruneti, C.; Ventura, M.; et al. Claimed effects, outcome variables and methods of measurement for health claims proposed under Regulation (EC) 1924/2006 in the framework of bone health. PharmaNutrition 2018, 6, 17–36. [Google Scholar] [CrossRef]
  11. Martini, D.; Galli, C.; Guareschi, C.; Angelino, D.; Bedogni, G.; Biasini, B.; Zavaroni, I.; Pruneti, C.; Ventura, M.; Galli, D.; et al. Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under Regulation (EC) 1924/2006 in the area of oral health. NFS J. 2018, 10, 10–25. [Google Scholar] [CrossRef]
  12. Kniestedt, C.; Stamper, R.L. Visual acuity and its measurement. Ophthalmol. Clin. N. Am. 2003, 16, 155–170. [Google Scholar] [CrossRef]
  13. International Council of Ophthalmology. Visual Standards—Aspects and Ranges of Vision Loss; Report prepared for the International Council of Ophthalmology at the 29th International Congress of Ophthalmology; International Council of Ophthalmology: Sydney, Australia, 2002. [Google Scholar]
  14. Ricci, F.; Cedrone, C.; Cerulli, L. Standardized measurement of visual acuity. Ophthalmic Epidemiol. 1998, 5, 41–53. [Google Scholar] [CrossRef] [PubMed]
  15. Tidbury, L.P.; Czanner, G.; Newsham, D. Fiat lux: The effect of illuminance on acuity testing. Graefe’s Arch. Clin. Exp. Ophthalmol. 2016, 254, 1091–1097. [Google Scholar] [CrossRef] [PubMed]
  16. Wubben, T.; Wolfe, G.; Guerrero, C.; Korcz, W.J.; Ramsey, D.J. Near visual acuity in an inner city Hispanic community: Understanding the barriers and benefits of correction. Community Eye Health 2014, 27, 41–42. [Google Scholar] [PubMed]
  17. Richman, J.; Spaeth, G.L.; Wirostko, B. Contrast sensitivity basics and a critique of currently available tests. J. Cataract Refract. Surg. 2013, 39, 1100–1106. [Google Scholar] [CrossRef] [PubMed]
  18. Mantyjarvi, M.; Laitinen, T. Normal values for the Pelli-Robson contrast sensitivity test. J. Cataract Refract. Surg. 2001, 27, 261–266. [Google Scholar] [CrossRef]
  19. Thayaparan, K.; Crossland, M.D.; Rubin, G.S. Clinical assessment of two new contrast sensitivity charts. Br. J. Ophthalmol. 2007, 91, 749–752. [Google Scholar] [CrossRef] [PubMed]
  20. Gruber, N.; Mosimann, U.P.; Muri, R.M.; Nef, T. Vision and night driving abilities of elderly drivers. Traffic Inj. Prev. 2013, 14, 477–485. [Google Scholar] [CrossRef] [PubMed]
  21. Aslam, T.M.; Haider, D.; Murray, I.J. Principles of disability glare measurement: An ophthalmological perspective. Acta Ophthalmol. Scand. 2007, 85, 354–360. [Google Scholar] [CrossRef] [PubMed]
  22. Franssen, L.; Coppens, J.E.; van den Berg, T.J. Compensation comparison method for assessment of retinal straylight. Investig. Ophthalmol. Vis. Sci. 2006, 47, 768–776. [Google Scholar] [CrossRef] [PubMed]
  23. Van den Berg, T.J.; Franssen, L.; Kruijt, B.; Coppens, J.E. History of ocular straylight measurement: A review. Z. Med. Phys. 2013, 23, 6–20. [Google Scholar] [CrossRef] [PubMed]
  24. Grobbel, J.; Dietzsch, J.; Johnson, C.A.; Vonthein, R.; Stingl, K.; Weleber, R.G.; Schiefer, U. Normal values for the full visual field, corrected for age- and reaction time, using semiautomated kinetic testing on the octopus 900 perimeter. Transl. Vis. Sci. Technol. 2016, 5. [Google Scholar] [CrossRef] [PubMed]
  25. Spector, R. Visual fields. In Clinical Methods: The History, Physical, and Laboratory Examinations, 3rd ed.; Kenneth Walker, H., Dallas Hall, W., Willis Hurst, J., Eds.; Butterworths: Boston, MA, USA, 1990. [Google Scholar]
  26. Nordmann, J.P.; Mesbah, M.; Berdeaux, G. Scoring of visual field measured through Humphrey perimetry: Principal component varimax rotation followed by validated cluster analysis. Invest. Ophthalmol. Vis. Sci. 2005, 46, 3169–3176. [Google Scholar] [CrossRef] [PubMed]
  27. Rowe, F.J.; Sarkies, N.J. Assessment of visual function in idiopathic intracranial hypertension: A prospective study. Eye 1998, 12, 111–118. [Google Scholar] [CrossRef] [PubMed]
  28. Dhalla, M.S.; Fantin, A.; Blinder, K.J.; Bakal, J.A. The macular automated photostress test. Am. J. Ophthalmol. 2007, 143, 596–600. [Google Scholar] [CrossRef] [PubMed]
  29. Loughman, J.; Ratzlaff, M.; Foerg, B.; Connell, P. Suitability and repeatability of a photostress recovery test device, the macular degeneration detector (MDD-2), for diabetes and diabetic retinopathy assessment. Retina 2014, 34, 1006–1013. [Google Scholar] [CrossRef] [PubMed]
  30. Phurailatpam, J. Evoked potentials: Visual evoked potentials (VEPs): Clinical uses, origin, and confounding parameters. J. Med. Soc. 2014, 28, 140–144. [Google Scholar] [CrossRef]
  31. Kothari, R.; Bokariya, P.; Singh, S.; Singh, R. A comprehensive review on methodologies employed for visual evoked potentials. Scientifica 2016, 2016, 9852194. [Google Scholar] [CrossRef] [PubMed]
  32. Lenassi, E.; Likar, K.; Stirn-Kranjc, B.; Brecelj, J. VEP maturation and visual acuity in infants and preschool children. Doc. Ophthalmol. 2008, 117, 111–120. [Google Scholar] [CrossRef] [PubMed]
  33. Norcia, A.M.; Tyler, C.W. Spatial frequency sweep VEP: Visual acuity during the first year of life. Vis. Res. 1985, 25, 1399–1408. [Google Scholar] [CrossRef]
  34. Salomao, S.R.; Ejzenbaum, F.; Berezovsky, A.; Sacai, P.Y.; Pereira, J.M. Age norms for monocular grating acuity measured by sweep-VEP in the first three years of age. Arq. Bras. Oftalmol. 2008, 71, 475–479. [Google Scholar] [CrossRef] [PubMed]
  35. Birch, E.E.; Morale, S.E.; Jeffrey, B.G.; O’Connor, A.R.; Fawcett, S.L. Measurement of stereoacuity outcomes at ages 1 to 24 months: Randot stereocards. J. AAPOS 2005, 9, 31–36. [Google Scholar] [CrossRef] [PubMed]
  36. Julesz, B. Binocular depth perception of computer-generated patterns. Bell Syst. Tech. J. 1960, 39, 1125–1162. [Google Scholar] [CrossRef]
  37. Birch, E.E.; Salomao, S. Infant random dot stereoacuity cards. J. Pediatr. Ophthalmol. Strabismus 1998, 35, 86–90. [Google Scholar] [PubMed]
  38. Birch, E.; Williams, C.; Drover, J.; Fu, V.; Cheng, C.; Northstone, K.; Courage, M.; Adams, R. Randot preschool stereoacuity test: Normative data and validity. J. AAPOS 2008, 12, 23–26. [Google Scholar] [CrossRef] [PubMed]
  39. Lee, J.; Birtles, D.; Wattam-Bell, J.; Atkinson, J.; Braddick, O. Latency measures of pattern-reversal VEP in adults and infants: Different information from transient P1 response and steady-state phase. Investig. Ophthalmol. Vis. Sci. 2012, 53, 1306–1314. [Google Scholar] [CrossRef] [PubMed]
  40. American Clinical Neurophysiology Society. Guideline 9b: Guidelines on visual evoked potentials. J. Clin. Neurophysiol. 2006, 23, 138–156. [Google Scholar]
  41. Simon, J.W.; Siegfried, J.B.; Mills, M.D.; Calhoun, J.H.; Gurland, J.E. A new visual evoked potential system for vision screening in infants and young children. J. AAPOS 2004, 8, 549–554. [Google Scholar] [CrossRef] [PubMed]
  42. Cavallini, A.; Fazzi, E.; Viviani, V.; Astori, M.G.; Zaverio, S.; Bianchi, P.E.; Lanzi, G. Visual acuity in the first two years of life in healthy term newborns: An experience with the teller acuity cards. Funct. Neurol. 2002, 17, 87–92. [Google Scholar] [PubMed]
  43. Hall, H.L.; Courage, M.L.; Adams, R.J. The predictive utility of the teller acuity cards for assessing visual outcome in children with preterm birth and associated perinatal risks. Vis. Res. 2000, 40, 2067–2076. [Google Scholar] [CrossRef]
  44. Sernagor, E. Retinal development: Second sight comes first. Curr. Biol. 2005, 15, R556–R559. [Google Scholar] [CrossRef] [PubMed]
  45. Jandeck, C.; Kellner, U.; Helbig, H.; Versmold, H.; Foerster, M.H. Natural course of retinal development in preterm infants without threshold retinopathy. Ger. J. Ophthalmol. 1995, 4, 131–136. [Google Scholar] [PubMed]
  46. Harden, A.; Adams, G.G.; Taylor, D.S. The electroretinogram. Arch. Dis. Child. 1989, 64, 1080–1087. [Google Scholar] [CrossRef] [PubMed]
  47. Zhou, X.; Huang, X.; Chen, H.; Zhao, P. Comparison of electroretinogram between healthy preterm and term infants. Doc. Ophthalmol. 2010, 121, 205–213. [Google Scholar] [CrossRef] [PubMed]

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.